Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR142 | Q7Z601 | 12/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | VCP | P55072 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.45 |
| ▸ | AGER | Q15109 | 1/20 | 0.44 |
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2686204 | 0.88 | GPR142 (0.62) | GPR142AKT1LNPEPCDC7ROCK2 | |
| SCHEMBL2686199 | 0.88 | GPR142 (0.62) | GPR142AKT1LNPEPCDC7ROCK2 | |
| SCHEMBL13258455 | 0.82 | GPR142 (0.53) | GPR142 | |
| SCHEMBL2685421 | 0.80 | GPR142 (0.68) | GPR142AKT1CDC7ROCK2MAP4K4 | |
| SCHEMBL2685425 | 0.80 | GPR142 (0.68) | GPR142AKT1CDC7ROCK2MAP4K4 | |
| SCHEMBL2686274 | 0.79 | GPR142 (0.67) | GPR142AKT1CDC7ROCK2MAP4K4 | |
| SCHEMBL4520427 | 0.79 | GPR142 (0.64) | GPR142AKT1CDC7ROCK2MAP4K4 | |
| SCHEMBL2686269 | 0.79 | GPR142 (0.67) | GPR142AKT1CDC7ROCK2MAP4K4 | |
| SCHEMBL2802593 | 0.75 | ROCK2 (0.64) | GPR142AKT1ROCK2GSK3BCLK4 | |
| SCHEMBL10260826 | 0.75 | ROCK2 (0.64) | GPR142AKT1ROCK2GSK3BCLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785468-B2 | Phenylalanine amide derivatives useful for treating insulin-related diseases and conditions | AMGEN INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2012-05-10 | — | — | US | disclosed |
| WO-2010093849-A2 | PHENYLALANINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | AMGEN INC. (US) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115811-A1 | PHENYLANALINE AMIDE DERIVATIVES USEFUL FOR TREATING INSULIN-RELATED DISEASES AND CONDITIONS | IAPP, INSR, AMY2A | GPR142 2779/4885PPARG 233/4885VCP 2168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.